Martin Lohse

Martin Lohse

Auto-generated profile, based on publicly available information

Martin Lohse

Department of Analytical Chemistry, Helmholtz Centre for Environmental Research – UFZ, 04318 Leipzig, Germany

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 June 1990 in Science
Verified
Journal Article
Closed access
PDF file
MLMartin J. Lohse
Martin J. Lohse
JBJeffrey L. Benovic
Jeffrey L. Benovic
JCJuan Codina
Juan Codina
MCMarc G. Caron
Marc G. Caron
RLRobert J. Lefkowitz
Robert J. Lefkowitz
Homologous or agonist-specific desensitization of β-adrenergic receptors is thought to be mediated by a specific kinase, the β-adrenergic receptor kinase (βARK). However, recent data suggest that a cofactor is required for this kinase to inhibit receptor function. The complementary DNA for such a cofactor was cloned and found to encode a 418-amino acid protein homologous to the retinal protein arrestin. The protein, termed β-arrestin, was expressed and partially purified. It inhibited the signaling function of βARK-phosphorylated β-adrenergic receptors by more than 75 percent, but not that of rhodopsin. It is proposed that β-arrestin in concert with βARK effects homologous desensitization of β-adrenergic receptors.

14 November 2003 in Circulation Research
Verified
Journal Article
Closed access
MLMartin J. Lohse
Martin J. Lohse
SEStefan Engelhardt
Stefan Engelhardt
TEThomas Eschenhagen
Thomas Eschenhagen
This review addresses open questions about the role of β-adrenergic receptors in cardiac function and failure. Cardiomyocytes express all three β-adrenergic receptor subtypes—β 1 , β 2 , and, at least in some species, β 3 . The β 1 subtype is the most prominent one and is mainly responsible for positive chronotropic and inotropic effects of catecholamines. The β 2 subtype also increases cardiac function, but its ability to activate nonclassical signaling pathways suggests a function distinct from the β 1 subtype. In heart failure, the sympathetic system is activated, cardiac β-receptor number and function are decreased, and downstream mechanisms are altered. However, in spite of a wealth of data, we still do not know whether and to what extent these alterations are adaptive/protective or detrimental, or both. Clinically, β-adrenergic antagonists represent the most important advance in heart failure therapy, but it is still debated whether they act by blocking or by resensitizing the β-adrenergic receptor system. Newer experimental therapeutic strategies aim at the receptor desensitization machinery and at downstream signaling steps.

1 September 2004 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
VNViacheslav O. Nikolaev
Viacheslav O. Nikolaev
MBMoritz Bünemann
Moritz Bünemann
LHLutz Hein
Lutz Hein
AHAnnette Hannawacker
Annette Hannawacker
MLMartin J. Lohse
Martin J. Lohse
CAMP is a universal second messenger of many G-protein-coupled receptors and regulates a wide variety of cellular events. cAMP exerts its effects via cAMP-dependent protein kinase (PKA), cAMP-gated ion channels, and two isoforms of exchange protein directly activated by cAMP (Epac). Here we report the development of novel fluorescent indicators for cAMP based on the cAMP-binding domains of Epac and PKA. Fluorescence resonance energy transfer between variants of green fluorescent protein (enhanced cyan fluorescent protein and enhanced yellow fluorescent protein) fused directly to the cAMP-binding domains was used to analyze spatial and temporal aspects of cAMP-signaling in different cells. In contrast to previously developed PKA-based indicators, these probes are comprised of only a single binding site lacking cooperativity, catalytic properties, and interactions with other proteins and thereby allow us to easily image free intracellular cAMP and rapid signaling events. Rapid β-adrenergic receptor-induced cAMP signals were observed to travel with high speed (≈40 μm/s) throughout the entire cell body of hippocampal neurons and peritoneal macrophages. The developed indicators could be ubiquitously applied to studying cAMP, its physiological role and spatio-temporal regulation.

1 February 1993 in Circulation
Verified
Journal Article
Closed access
MUM Ungerer
M Ungerer
MBM Böhm
M Böhm
JEJ S Elce
J S Elce
EEE Erdmann
E Erdmann
MLM J Lohse
M J Lohse
BACKGROUND: In chronic heart failure, the positive inotropic effects of beta-adrenergic receptor agonists are greatly reduced, in part as a result of two alterations of the cardiac beta-adrenergic receptors: loss of their function (receptor uncoupling) and reduction of their number (downregulation). In vitro studies have shown that a major mechanism leading to beta-adrenergic receptor uncoupling involves phosphorylation of the receptors by the specific beta-adrenergic receptor kinase (beta ARK). METHODS AND RESULTS: We have therefore investigated expression of beta ARK and beta-adrenergic receptors in samples from the left ventricles of patients with dilated cardiomyopathy or ischemic cardiomyopathy and from nonfailing control ventricles. Contractile responses to beta-receptor stimulation were decreased in the failing hearts compared with control hearts, whereas those to forskolin and calcium remained unchanged. The messenger RNA (mRNA) levels of beta ARK, beta 1- and beta 2-receptors, and of glyceraldehyde phosphate dehydrogenase and beta-actin as controls were measured by quantitative polymerase chain reactions. In addition, beta ARK enzyme activity assays were performed, and the levels of beta 1- and beta 2-receptors were determined by radioligand binding. beta ARK mRNA levels were increased almost threefold in both forms of heart failure, and beta ARK activity was enhanced. beta 1-Receptor mRNA levels and beta 1-receptor numbers were decreased by approximately 50% in both failing groups, whereas these levels were unaltered for beta 2-receptors. There were no differences between dilated and ischemic cardiomyopathy for any of these parameters. CONCLUSIONS: In addition to other alterations found in failing hearts, the diminished response to beta-receptor agonists appears to involve the combined effects of enhanced expression of beta ARK and reduced expression of beta 1-receptors.

8 June 1999 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
SEStefan Engelhardt
Stefan Engelhardt
LHLutz Hein
Lutz Hein
FWFrank Wiesmann
Frank Wiesmann
MLMartin J. Lohse
Martin J. Lohse
Stimulation of cardiac β 1 -adrenergic receptors is the main mechanism that increases heart rate and contractility. Consequently, several pharmacological and gene transfer strategies for the prevention of heart failure aim at improving the function of the cardiac β-adrenergic receptor system, whereas current clinical treatment favors a reduction of cardiac stimulation. To address this controversy, we have generated mice with heart-specific overexpression of β 1 -adrenergic receptors. Their cardiac function was investigated in organ bath experiments as well as in vivo by cardiac catheterization and by time-resolved NMR imaging. The transgenic mice had increased cardiac contractility at a young age but also developed marked myocyte hypertrophy (3.5-fold increase in myocyte area). This increase was followed by progressive heart failure with functional and histological deficits typical for humans with heart failure. Contractility was reduced by ≈50% in 35-week-old mice, and ejection fraction was reduced down to a minimum of ≈20%. We conclude that overexpression of β 1 -adrenergic receptors in the heart may lead to a short-lived improvement of cardiac function, but that increased β 1 -adrenergic receptor signalling is ultimately detrimental.

1 April 2014 in Pharmacological Reviews
Verified
Journal Article
Closed access
PDF file
SFSergi Ferre
Sergi Ferre
VCVicent Casadó
Vicent Casadó
LDLakshmi A. Devi
Lakshmi A. Devi
MFMarta Filizola
Marta Filizola
RJRalf Jockers
Ralf Jockers
XGXavier Guitart
Xavier Guitart
Most evidence indicates that, as for family C G protein–coupled receptors (GPCRs), family A GPCRs form homo- and heteromers. Homodimers seem to be a predominant species, with potential dynamic formation of higher-order oligomers, particularly tetramers. Although monomeric GPCRs can activate G proteins, the pentameric structure constituted by one GPCR homodimer and one heterotrimeric G protein may provide a main functional unit, and oligomeric entities can be viewed as multiples of dimers. It still needs to be resolved if GPCR heteromers are preferentially heterodimers or if they are mostly constituted by heteromers of homodimers. Allosteric mechanisms determine a multiplicity of possible unique pharmacological properties of GPCR homomers and heteromers. Some general mechanisms seem to apply, particularly at the level of ligand-binding properties. In the frame of the dimer-cooperativity model, the two-state dimer model provides the most practical method to analyze ligand–GPCR interactions when considering receptor homomers. In addition to ligand-binding properties, unique properties for each GPCR oligomer emerge in relation to different intrinsic efficacy of ligands for different signaling pathways (functional selectivity). This gives a rationale for the use of GPCR oligomers, and particularly heteromers, as novel targets for drug development. Herein, we review the functional and pharmacological properties of GPCR oligomers and provide some guidelines for the application of discrete direct screening and high-throughput screening approaches to the discovery of receptor-heteromer selective compounds.